Evans John M. 4

What Happened
John M. Evans, CEO and director of Beam Therapeutics (BEAM), disposed of 30,078 shares on April 1, 2026 at $24.58 per share for total proceeds of $739,317. The filing shows the shares were automatically sold to cover tax withholding obligations related to vested restricted stock units.

Key Details

• Transaction date and price: 2026-04-01 — 30,078 shares sold at $24.58 each; proceeds $739,317.
• Transaction type: Sale (reported as S); non‑discretionary automatic sale to cover taxes (footnote F1).
• 10b5‑1 plan: Sales were effected under a Rule 10b5‑1 trading plan adopted May 19, 2023 (per F1).
• ESPP note: Footnote F2 reports 616 shares were acquired under the company ESPP on March 31, 2026.
• Shares owned after transaction: Not specified in this filing.
• Filing timeliness: Form 4 was filed April 6, 2026 for an April 1 transaction — this is later than the typical 2-business-day Form 4 deadline.

Context
This sale was a routine tax-withholding disposition tied to RSU vesting and executed under a pre-established 10b5‑1 plan, which is commonly viewed as administrative rather than a signal about insider sentiment. The small ESPP purchase noted is routine employee participation. The late filing means the market received disclosure later than the usual reporting window.